188 related articles for article (PubMed ID: 29732393)
1. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
[TBL] [Abstract][Full Text] [Related]
2. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
3. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
Shao C; He J; Kachroo S; Jin F
Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
[TBL] [Abstract][Full Text] [Related]
4. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer.
Mehta S; Xie J; Ionescu-Ittu R; Nie X; Kwong WJ
Oncol Ther; 2023 Dec; 11(4):481-493. PubMed ID: 37715853
[TBL] [Abstract][Full Text] [Related]
6. Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact
Bueno APA; Clark O; Turnure M; Moreira ES; Chang J; Hou N; Li S; Kim R; Kearney M; Kirker M; Kanas G
Future Oncol; 2024 Mar; 20(10):613-622. PubMed ID: 37357780
[TBL] [Abstract][Full Text] [Related]
7. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States.
Geynisman DM; Broughton E; Hao Y; Zhang Y; Le T; Huo S
Urol Oncol; 2022 May; 40(5):195.e1-195.e11. PubMed ID: 34906410
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer.
Beigi A; Vafaei-Nodeh S; Huang L; Sun SZ; Ko JJ
Curr Oncol; 2021 Sep; 28(5):3812-3824. PubMed ID: 34677243
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study.
Shao C; He J; Stein K; Keefe S
Curr Med Res Opin; 2020 Jul; 36(7):1187-1194. PubMed ID: 32314603
[No Abstract] [Full Text] [Related]
10. Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Bilen MA; Robinson SB; Schroeder A; Peng J; Kim R; Liu FX; Bhanegaonkar A
Oncologist; 2023 Sep; 28(9):790-798. PubMed ID: 37432283
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns, Clinical Outcomes, Health Care Resource Utilization and Costs in Older Patients With Metastatic Castration-Resistant Prostate Cancer in the United States: An Analysis of SEER-Medicare Data.
Swami U; Aggarwal H; Zhou M; Jiang S; Kim J; Li W; Laliberté F; Emond B; Agarwal N
Clin Genitourin Cancer; 2023 Oct; 21(5):517-529. PubMed ID: 37248148
[TBL] [Abstract][Full Text] [Related]
12. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy.
Morgans AK; Grewal S; Hepp Z; Fuldeore R; Odak S; Macahilig C; Shillington AC; Sonpavde G
Clin Genitourin Cancer; 2022 Dec; 20(6):543-552. PubMed ID: 36088235
[TBL] [Abstract][Full Text] [Related]
15. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study.
Flannery K; Boyd M; Black-Shinn J; Robert N; Kamat AM
Future Oncol; 2019 Apr; 15(12):1323-1334. PubMed ID: 30942088
[No Abstract] [Full Text] [Related]
17. Survival, Chemotherapy Treatments, and Health Care Utilization Among Patients with Advanced Small Cell Lung Cancer: An Observational Study.
He J; Shao C; Hui SL; Zhang Z; Baker J; Dexter PR; Kachroo S; Jin F
Adv Ther; 2020 Jan; 37(1):552-565. PubMed ID: 31828610
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
Gynecol Oncol Rep; 2022 Dec; 44(Suppl 1):101101. PubMed ID: 36506039
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
Gynecol Oncol Rep; 2022 Dec; 44():101121. PubMed ID: 36589508
[TBL] [Abstract][Full Text] [Related]
20. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
